1009119-65-6 | Daclatasvir dihydrochloride

Packsize	Purity	Availability	Price	Discounted Price
10mg	98%	in stock	$15.00	$10.00
50mg	98%	in stock	$18.00	$12.00
100mg	98%	in stock	$22.00	$15.00
250mg	98%	in stock	$26.00	$18.00
1g	98%	in stock	$56.00	$39.00
5g	98%	in stock	$256.00	$179.00

Description

• Catalog Number: AA03923
• Chemical Name: Daclatasvir dihydrochloride
• CAS Number: 1009119-65-6
• Molecular Formula: C40H52Cl2N8O6
• Molecular Weight: 811.7969
• MDL Number: MFCD25541736
• SMILES: COC(=O)N[C@H](C(=O)N1CCC[C@H]1c1ncc([nH]1)c1ccc(cc1)c1ccc(cc1)c1cnc([nH]1)[C@@H]1CCCN1C(=O)[C@H](C(C)C)NC(=O)OC)C(C)C.Cl.Cl

Computed Properties

• Complexity: 1190
• Covalently-Bonded Unit Count: 3
• Defined Atom Stereocenter Count: 4
• Heavy Atom Count: 56
• Hydrogen Bond Acceptor Count: 8
• Hydrogen Bond Donor Count: 6
• Rotatable Bond Count: 13

Literature

• Biotransformation of Daclatasvir In Vitro and in Nonclinical Species: Formation of the Main Metabolite by Pyrrolidine δ-Oxidation and Rearrangement.

  Drug metabolism and disposition: the biological fate of chemicals 20160601

• Daclatasvir: A NS5A Replication Complex Inhibitor for Hepatitis C Infection.

  The Annals of pharmacotherapy 20160101

• Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors.

  Bioorganic & medicinal chemistry letters 20150901

• Design and synthesis of imidazole N-H substituted amide prodrugs as inhibitors of hepatitis C virus replication.

  Bioorganic & medicinal chemistry letters 20150815

• Daclatasvir-like inhibitors of NS5A block early biogenesis of hepatitis C virus-induced membranous replication factories, independent of RNA replication.

  Gastroenterology 20141101

• Hepatitis C virus NS5A replication complex inhibitors: the discovery of daclatasvir.

  Journal of medicinal chemistry 20140313

• Synthesis and evaluation of non-dimeric HCV NS5A inhibitors.

  Bioorganic & medicinal chemistry letters 20130401

• Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life.

  Proceedings of the National Academy of Sciences of the United States of America 20130305

• Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

  Antimicrobial agents and chemotherapy 20130301

• Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.

  Antimicrobial agents and chemotherapy 20130301

• HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.

  Bioorganic & medicinal chemistry letters 20130201

• Daclatasvir: potential role in hepatitis C.

  Drug design, development and therapy 20130101

• HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.

  Bioorganic & medicinal chemistry letters 20121001

• Correlation between NS5A dimerization and hepatitis C virus replication.

  The Journal of biological chemistry 20120831

• A sensitive and accurate liquid chromatography-tandem mass spectrometry method for quantitative determination of the novel hepatitis C NS5A inhibitor BMS-790052 (daclastasvir) in human plasma and urine.

  Journal of chromatography. A 20120706

• In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A.

  Antimicrobial agents and chemotherapy 20120301

• Treatment of chronic hepatitis C--are interferons really necessary?

  Liver international : official journal of the International Association for the Study of the Liver 20120201

• Preliminary study of two antiviral agents for hepatitis C genotype 1.

  The New England journal of medicine 20120119

• Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action.

  Journal of virology 20110701

• Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system.

  Antimicrobial agents and chemotherapy 20100901

• Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.

  Nature 20100506